ClinicalTrials.gg
RecruitingNCT06475352FUDOSEUpdated Apr 23, 2026

Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

A Phase 2 interventional study of FOLFOX regimen and CAPOX regimen in Digestive Cancer and Colorectal Cancer, sponsored by UNICANCER. Recruiting at 41 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Primary conditionColorectal NeoplasmsRegistry: Gastrointestinal NeoplasmsReclassifiedWhy we changed it
Registry
Gastrointestinal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colorectal Neoplasms
Why
  1. The study's listed conditions name Colorectal Neoplasms, a narrower term within Gastrointestinal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by UNICANCER · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies testing Folfox protocol in Colorectal Neoplasms — 14 open to participants now, 17 under way, 3 of them phase 3. Folfox protocol · Colorectal Neoplasms.

Planned enrollment
9th of 37
400 · median 102
Started
2025
with 3 others
Phase 2
19 of 37
8 open now
Primary completion
2027-04
later than 6 of 16 live
Registered
30th of 37
by date

Among the 37 studies testing Folfox protocol in Colorectal Neoplasms, this one is the 9th largest by planned enrollment, is one of 4 that started in 2025, is one of 19 in phase 2, reaches primary completion later than 6 of the 16 other live ones, and was the 30th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

14 of the 37 studies testing Folfox protocol in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Folfox protocol

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing Folfox protocol in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to establish guidelines for fluoropyrimidine dose reduction according to uracilemia in patients with DPD deficiency in the treatment of digestive cancers. The main question it aims to answer is:

- Which reduction dose of fluoropyrimidine is needed for patient with DPD deficiency?

Participants will:

  • Take the treatment with the reduction of dose stated by the protocol
  • Visit the clinic once every 2-3 weeks for checkups and tests for collection of adverse events
Read the detailed description

Multicenter phase II trial evaluating different strategies of pre-specified fluoropyrimidine-dose adjustment according to [U] in DPD-deficient patients with gastrointestinal cancer.

03

Conditions studied

  • Digestive Cancer
  • Colorectal Cancer

Keywords

  • Fluoropyrimidine
  • FOLFOX
  • CAPOX
  • Adjuvant
  • Metastatic
  • Recurrent
  • Colorectal
  • digestive
  • Cancer
04

In context

Colorectal Neoplasms Reclassified

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

This study's planned enrollment of 400 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

UNICANCER is the lead sponsor of 219 studies on the registry; 52 are open to participants now.

Compared within Colorectal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gastrointestinal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with pre-treatment screening based on [U] value according to INCa/HAS recommendations.
  2. performance status (ECOG PS) ≤2
  3. Fluoropyrimidine-naïve patients with gastrointestinal cancer starting chemotherapy combining fluoropyrimidine (5-FU or capecitabine) and oxaliplatin whatever the context (adjuvant, , palliative) including the following regimens (the most frequently prescribed in gastrointestinal cancers):

    • biweekly 5-FU and oxaliplatin (FOLFOX) +/- targeted therapy (TT)
    • three-weekly capecitabine and oxaliplatin (CAPOX) +/- TT
  4. Age ≥ 18 years
  5. Patients eligible for full standard fluoropyrimidine and oxaliplatin doses regardless of DPD deficiency
  6. Adequate bone marrow function (cell blood count (CBC)), estimated (DFG) ≥ 50 ml/min, alkaline phosphatase (ALP) / (ASAT) / alanine aminotransferase (ALAT) ≤ 5 (ULN), and ≤ 50 micromol/L
  7. Patient must have signed and dated a written form prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent.
  8. Women of must have a negative serum or urine pregnancy test.
  9. Patients must agree to remain abstinent or use methods with a failure rate of \< 1% per year for the duration of study treatment and within 6 months after completing treatment.
  10. Patients must be affiliated to a Social Security System (or equivalent).
  11. Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Patients with complete DPD deficiency based on [U] ≥150 ng/mL
  2. Any prior treatment including a fluoropyrimidine
  3. Patients with any to treatment with fluoropyrimidine or oxaliplatin regardless of DPD deficiency
  4. Patients not eligible for full standard dose fluoropyrimidine and oxaliplatin for clinical reasons including older age and/or comorbidity regardless of a DPD deficiency
  5. Patients unwilling or unable to comply with trial obligations for geographic, social, or physical reasons, or who are unable to understand the purpose and procedures of the trial
  6. Recent or concomitant treatment with brivudine
  7. Pregnant or breastfeeding woman.
  8. Participation in another therapeutic trial within 30 days prior to inclusion.
  9. Persons deprived of their liberty or under protective custody or guardianship.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    Uracilemia <16

    Patient with uracilemia \<16 ng/mL will receive a full standard fluoropyrimidine dose

    Drug: FOLFOX regimen · Drug: CAPOX regimen

  • Experimental
    Uracilemia [16-20[

    Patients with uracilemia between \[16-20\[ ng/mL will receive a full standard fluoropyrimidine dose -dose

    Drug: FOLFOX regimen · Drug: CAPOX regimen

  • Experimental
    Uracilemia [20-50[ - 25%

    Patients with uracilemia between \[20-50\[ ng/mL will be randomized to receive a 25% fluoropyrimidine dose reduction

    Drug: FOLFOX regimen · Drug: CAPOX regimen

  • Experimental
    Uracilemia [20-50[ - 50%

    Patients with uracilemia between \[20-50\[ ng/mL will be randomized to receive a 50% fluoropyrimidine dose reduction

    Drug: FOLFOX regimen · Drug: CAPOX regimen

  • Experimental
    Uracilemia [50-100[

    Patients with uracilemia between \[50-100\[ ng/mL will receive a 50% fluoropyrimidine dose reduction

    Drug: FOLFOX regimen · Drug: CAPOX regimen

  • Experimental
    Uracilemia [100-150[

    Patients with uracilemia between \[100-150\[ ng/mL will receive a 75% fluoropyrimidine dose reduction

    Drug: FOLFOX regimen · Drug: CAPOX regimen

Interventions

  • DrugFolfox protocolStudies of Folfox protocolFolfox protocol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oxaliplatin will be administered at a fixed dose of 85 mg/m² by 2h intravenous (IV) infusion concurrently with folinic acid 400 mg/m² (or 200 mg/m² if L-folinic acid) as a 2 h IV infusion on day 1 of each 14-day cycle followed by 5-fluorouracil (5-FU) 400 mg/m² IV bolus on day 1, then continuous IV infusion of 1,200 mg/m² /day × 2 days (total 2400 mg/m² for 46-48 hours)

  • DrugCAPOX regimen

    Oxaliplatin will be administered at a fixed dose of 130 mg/m² by 2h IV infusion on day 1 of each 21-day cycle followed by capecitabine (1000 mg/m²) twice a day (BID) during 2 weeks, every 3 weeks

07

What researchers measure

Primary outcomes

  1. Proportion of fluoropyrimidine-induced grade ≥ 3 haematological and gastrointestinal toxicity after 2 cycles

    The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

    Time frame: Throughout the two first cycles of treatment, up to 42 days

Secondary outcomes

  1. Recommended fluoropyrimidine dose

    The rate of fluoropyrimidine induced grade ≥ 3 haematological and gastrointestinal toxicity in each uracilemia-based group of DPD-deficient patients (according to uracilemia level) compared to the rate observed in non DPD-deficient patients (control arm)

    Time frame: Throughout the four first cycles of treatment, up to 3 months

  2. Description of fluoropyrimidine dose

    The cumulative dose (mg/m²) of chemotherapy delivered to patients will be recorded along with reasons of dose-modifications or treatment discontinuation for limiting toxicity

    Time frame: Throughout the four first cycles of treatment, up to 3 months

  3. Percentage of fluoropyrimidine dose modification

    Percentage of patients for whom fluoropyrimidine dose is increased or decreased

    Time frame: Throughout the four first cycles of treatment, up to 3 months

  4. Fluoropyrimidine toxicity during the study

    The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

    Time frame: Throughout the four first cycles of treatment, up to 3 months

  5. Disease-free survival (DFS) - Stage III Colon Cancer

    Disease-free survival is defined as the delay between date of inclusion and tumor relapse (local, regional, or distant) or death from any cause, whichever occurs first.

    Time frame: 3 years

  6. Overall survival (OS) - Stage III Colon Cancer

    The overall survival is the length of time from randomization that patients enrolled in the study are still alive.

    Time frame: From randomization to death from any cause, up to 3 years.

  7. Progression-free survival (PFS) - Stage IV Colon Cancer

    The progression-free survival is the length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse.

    Time frame: From randomization to disease progression or death, up to 1 year.

08

Study locations

36 of 41 sites recruiting
  • CHU Amiens
    Amiens, 50054, France
    Recruiting
    • Vincent HAUTEFEUILLE, Dr. · Principal investigator
  • Hopital Henri Mondor
    Aurillac, France
    Recruiting
    • Daniela BURLACU · Principal investigator
  • Institut du Cancer Avignon Provence
    Avignon, 84000, France
    Recruiting
    • Clémence TOULLEC, Dr. · Principal investigator
  • CH Aunay Bayeux
    Bayeux, 14400, France
    Recruiting
    • Annie PEYTIER, Dr. · Principal investigator
  • CH Cote Basque
    Bayonne, 64109, France
    Recruiting
    • Franck AUDEMAR, Dr. · Principal investigator
  • CHU Besançon
    Besançon, 25000, France
    Recruiting
    • Angélique VIENOT, Dr. · Principal investigator
  • Centre François Baclesse
    Caen, 14000, France
    Recruiting
    • Stéphane CORBINAIS, Dr. · Principal investigator
  • Polyclinique du Parc - Centre d'Oncologie Maurice Tubiana
    Caen, 14000, France
    Recruiting
    • Maud VILLEMIN, Dr. · Principal investigator
  • Infirmerie Protestante
    Caluire-et-Cuire, France
    Not yet recruiting
    • Emmanuelle GRAILLOT · Principal investigator
  • CHU Clermont Ferrand
    Clermont-Ferrand, 63003, France
    Not yet recruiting
    • Morgane HELYON, Dr. · Principal investigator
  • Hopital Beaujon
    Clichy, 92110, France
    Recruiting
    • Mohamed BOUATTOUR, Dr. · Principal investigator
  • Hopital Henri Mondor
    Créteil, 94010, France
    Recruiting
    • Charlotte FENIOUX, Dr. · Principal investigator
  • CHU Dijon
    Dijon, 21079, France
    Recruiting
    • Come LEPAGE, Dr. · Principal investigator
  • GH Mutualiste de Grenoble
    Grenoble, 38028, France
    Recruiting
    • Camille HERVE, Dr. · Principal investigator
  • Hopital Privé Drome-Ardeche
    Guilherand-Granges, 07500, France
    Recruiting
    • Agnes PELAQUIER, Dr. · Principal investigator
  • Centre Oscar Lambret
    Lille, France
    Recruiting
    • Aurélien Dr CARNOT · Principal investigator
  • CHU Dupuytren
    Limoges, 87042, France
    Recruiting
    • Frédéric THUILLIER, Dr. · Principal investigator
  • Hopital Privé Jean Mermoz
    Lyon, 69008, France
    Recruiting
    • Jérome DESRAME, Dr. · Principal investigator
  • Centre Léon Bérard
    Lyon, 69373, France
    Recruiting
    • Clelia COUTZAC, Dr. · Principal investigator
  • Grand Hopital de l'Est Francilien
    Meaux, 77100, France
    Recruiting
    • Christophe LOCHER, Dr · Principal investigator
  • Hopital Nord Franche Comté - Site du Mittan
    Montbéliard, 25200, France
    Recruiting
    • Christophe BORG, Dr. · Principal investigator
  • Centre Antoine Lacassagne
    Nice, 06189, France
    Recruiting
    • Claire JARAUDIAS, Dr. · Principal investigator
  • CHU d'Orléans
    Orléans, 45067, France
    Recruiting
    • Jean-Paul LAGASSE, Dr. · Principal investigator
  • Institut Curie
    Paris, 75005, France
    Recruiting
    • Pauline VAFLARD, Dr. · Principal investigator
  • Hopital Saint Louis
    Paris, 75010, France
    Recruiting
    • Thomas APARICIO, Pr. · Principal investigator
  • Hopital Saint Antoine
    Paris, 75012, France
    Recruiting
    • Daniel LOPEZ TRABADA ATAZ, Dr. · Principal investigator
  • GH Diaconesses Croix St Simon
    Paris, 75020, France
    Recruiting
    • Olivier DUBREUIL, Dr. · Principal investigator
  • Hopital Européen Georges Pompidou
    Paris, France
    Recruiting
    • Aziz Pr ZAANAN · Principal investigator
  • CHU Bordeaux
    Pessac, 33600, France
    Recruiting
    • Denis SMITH, Dr. · Principal investigator
  • Hospices Civiles de Lyon
    Pierre-Bénite, 69495, France
    Recruiting
    • Marion CHAUVENET, Dr. · Principal investigator
  • CHU Poitiers
    Poitiers, 86000, France
    Recruiting
    • David TOUGERON, Pr. · Principal investigator
  • Hopital Robert Debré
    Reims, 51100, France
    Recruiting
    • Olivier BOUCHE, Pr. · Principal investigator
  • Institut Jean Godinot
    Reims, 51100, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Centre Eugene Marquis
    Rennes, France
    Not yet recruiting
    • Astrid LIEVRE · Principal investigator
  • CHU Rouen - Hopital Charles Nicoles
    Rouen, France
    Recruiting
    • Adrien Dr GRANCHER · Principal investigator
  • CH de Saint Malo
    St-Malo, 35403, France
    Recruiting
    • Anne-Sophie MOUSSADDAQ, Dr. · Principal investigator
  • Institut du Cancer de Strasbourg
    Strasbourg, 67033, France
    Recruiting
    • Meher BEN ABDELGHANI, Dr. · Principal investigator
  • CHU de Toulouse
    Toulouse, 31059, France
    Recruiting
    • Nadim FARES, Dr. · Principal investigator
  • Hopital Bretonneau
    Tours, 37044, France
    Recruiting
    • Thierry LECOMTE, Pr. · Principal investigator
  • CHRU Nancy
    Vandœuvre-lès-Nancy, France
    Not yet recruiting
    • Marie MULLER · Principal investigator
  • Gustave Roussy Cancer Campus
    Villejuif, 94805, France
    Recruiting
    • Valérie BOIGE, Dr. · Principal investigator
09

References and documents

Publications

  • Camilleri GM, Loriot MA, Teuff GL, Thuillier F, Bouche O, Narjoz C, Abdelghani MB, Herve C, Corbinais S, Locher C, Lecomte T, Villemin M, Tougeron D, Lepage C, Peytier A, Moussaddaq AS, Dubreuil O, Mabro M, Desrame J, Carvalho NS, Boige V. Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study. Dig Liver Dis. 2026 Jul;58(7):899-905. doi: 10.1016/j.dld.2026.04.016. Epub 2026 May 22. PubMed 42173726 ↗

Individual participant data

Plan to share: No — Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Apr 2027, 27 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 27 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2024
First posted
Jun 26, 2024
StartActual
Jan 20, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Jan 2030
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06475352
Lead sponsor
UNICANCER
Responsible party
Sponsor
First posted
Jun 26, 2024
Start date
Jan 20, 2025
Primary completion
Apr 2027 (estimated)
Completion
Jan 2030 (estimated)
Last update
Apr 23, 2026

Study contacts

Nicolas DE SOUSA CARVALHO
Contact
n-de-sousa@unicancer.fr
01 71 93 67 09
Laure MONARD
Contact
l-monard@unicancer.fr
01 73 79 73 09
Valérie BOIGE, MD
principal investigator · Gustave Roussy Cancer Campus
Marie-Anne LORIOT
study director · Hopital Europeen Georges Pompidou

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Folfox protocol

Start the discussion